Latest News

NetScientific on the rise again after PDS cancer trial


NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression.

Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS’s candidate PDS0101 in combination with two immune-modulating agents on 25 patients.

Dr Lauren Wood, PDS’ chief medical officer, said: “The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients”

The achievement of a 67% tumour reduction among all HPV16-positive cancer patients supports further clinical investigation of the Versamune platform’s potential ability to induce high levels of tumour-specific CD8+ killer T-cells that attack cancer, she added.

 “The interim data demonstrating that this response was limited only to patients with HVP16-positive cancer, and also the fact that all responding patients who have stayed on treatment continue to show ongoing responses after a median duration of 8 months solidifies our belief that PDS0101’s ability to generate a robust, targeted T-cell response.”

This might have the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options, Wood added. 

Shares in NetScientific, which holds 5.75% of PDS, rose 33% to 199p, effectively meaning the shares have doubled in two days.

The share price had already rocketed yesterday on news yesterday from another portfolio company, Proaxis, which struck a licensing deal with AstraZeneca PLC (LON:AZN) over the validation and global commercialisation of an assay associated with coronavirus vaccines.

Water Intelligence sees profits surge as it provided essential service during pandemic

Previous article

Brickability in strong position as booming demand puts squeeze on brick supplies

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News